Skip to main content
Clinical Trials/ISRCTN26461337
ISRCTN26461337
Active, Not Recruiting
Phase 3

Clinical Validation of a Non-Invasive Diagnostic Test for Adrenal Insufficiency using Comparative Pharmacodynamic Equivalence in a Patient Population Salivary Test of Adrenal Response to Liquid Intranasal Tetracosactide - Study 3 (STARLIT-3)

Sheffield Children's NHS Foundation Trust0 sites32 target enrollmentMay 22, 2024

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Adrenal insufficiency
Sponsor
Sheffield Children's NHS Foundation Trust
Enrollment
32
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 22, 2024
End Date
June 30, 2025
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Known adrenal insufficiency
  • 2\. Basal cortisol \<100 nmol/L or peak on SST \<200 nmol/L at time of diagnosis or since in last 6 months
  • 3\. Able to comply with passive drool salivary sampling requirements
  • 4\. Able to provide signed written informed consent
  • 5\. Age 4\-75 years

Exclusion Criteria

  • 1\. Ongoing pregnancy
  • 2\. Use of oestrogen\-containing hormonal contraception / Hormone Replacement Therapy (due to the effect on cortisol levels)
  • 3\. Co\-morbid condition requiring daily administration of a medication that interferes with the metabolism of glucocorticoids, e.g. known to affect corticosteroid\-binding globulin (CBG), including all oestrogens, or the hypothalamic\-pituitary\-adrenal (HPA) axis, such as loperamide, oral antifungals and opiates
  • 4\. Known and active protein losing disorder, e.g. enteropathy or nephrotic syndrome, which may result in a cortisol binding globulin abnormality
  • 5\. Known clinical or biochemical evidence of hepatic or renal disease. Creatinine over twice the upper limit of normal (ULN) or elevated liver function tests (alanine transaminase (ALT) or aspartate transaminase (AST) \>3 times the ULN
  • 6\. Current uncontrolled active infection (may include later in the trial at clinician's discretion if completely resolved)
  • 7\. Known or suspected alcohol dependence or drug misuse
  • 8\. Current smoker or vaper (or within 6 months of cessation)
  • 9\. Recent (within last 1 week) liquorice ingestion (preparations containing glycyrrhizic acid only)
  • 10\. History of known salivary gland or oral mucosa pathology or unable to produce a suitable salivary sample (e.g. as a consequence of drugs that cause dry mouth)

Outcomes

Primary Outcomes

Not specified

Similar Trials